Latest News on OGN

Financial News Based On Company


Advertisement
Advertisement

Sun Pharma Plans $4 Billion Loan To Refinance $11.75 Billion Organon Acquisition

https://www.sahi.com/news/sun-pharma-plans-4-billion-loan-to-refinance-11-75-billion-organon-acquisition
Sun Pharma is securing a $4 billion syndicated bank loan with five banks to refinance part of the bridge financing for its $11.75 billion acquisition of Organon & Co. This move converts short-term deal debt into longer-term structured debt, optimizing the borrowing structure for India's largest pharmaceutical buyout. The refinancing is supported by stable investment-grade ratings from Moody's (Baa1) and S&P (BBB+), and AAA ratings from CRISIL and ICRA.

Sun Pharma eyes $4 Bn loan for Organon buy

https://pharma.economictimes.indiatimes.com/news/mergers-and-acquisitions/sun-pharma-eyes-4-b-loan-for-organon-buy/135869214
Sun Pharmaceutical Industries is securing a $4 billion syndicated loan to refinance a portion of the bridge financing used for its $11.75 billion acquisition of US healthcare company Organon & Co. Five lead arrangers, including Citibank and MUFG, are committing around $800 million each for the five-year loan. The transaction is expected to launch into senior syndication this week, with additional lenders anticipated to join.

Organon & Co Lobbying Profile, 2022

https://www.opensecrets.org/federal-lobbying/clients/organon-co?client_id=163552&cycle=2022
This OpenSecrets profile details Organon & Co's lobbying activities for 2022, categorized under the Pharmaceuticals/Health Products industry. The company spent $980,000 in federal lobbying in 2026, with data updated as of July 23, 2026, covering January 1 - June 30. The page provides sections for a summary, hired firms, lobbyists, issues, agencies, bills, and related reports and images.

how InvestingPro’s fair value spotted Organon’s 72% healthcare gain By Investing.com

https://www.investing.com/news/investment-ideas/how-investingpros-fair-value-spotted-organons-72-healthcare-gain-93CH-5018351
InvestingPro's Fair Value analysis accurately identified Organon & Co. (NYSE:OGN) as undervalued in May 2025, when the stock was trading at $8.04. Despite initial investor concerns, the stock surged 72.5% to $13.89, validating the platform's methodology. This success highlights how InvestingPro's comprehensive valuation techniques can pinpoint mispriced opportunities and provide investors with a margin of safety.

Organon & Co stock hits 52-week high at 13.89 USD

https://ca.investing.com/news/stock-market-news/organon--co-stock-hits-52week-high-at-1389-usd-93CH-4947776
Organon & Co (OGN) stock has reached a new 52-week high, trading at 13.89 USD, reflecting a significant 84.44% increase over the past year. This milestone highlights the company's strong performance and growing investor confidence. The article emphasizes the company's robust growth and strategic market position.
Advertisement

New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System

https://www.quantisnow.com/insight/new-real-world-evidence-presented-by-organon-at-the-american-college-6779780
Organon presented real-world evidence at the American College of Rheumatology annual meeting regarding a large-scale switch from HUMIRA to its biosimilar, HADLIMA, within the United States Veterans Affairs Healthcare System. The study involving 16,322 veterans demonstrated a low 1.3% switchback rate over 12 months and estimated $132 million in savings for the VA, with an average first-year pharmacy cost decrease of $8,100 per patient. This data supports HADLIMA's continued adoption and its exclusive selection by the VA to replace HUMIRA on its national formulary in 2024.

A cream treats eczema in adults and children 2 and older. Organon will present a new analysis across patient groups.

https://www.stocktitan.net/news/OGN/organon-to-present-new-analysis-on-vtama-tapinarof-cream-1-at-the-xu81u0o9kvfe.html
Organon (NYSE: OGN) announced it will present new analysis of its Phase 3 VTAMA cream data at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting. This analysis evaluates the consistent efficacy of VTAMA cream across diverse patient subgroups with moderate to severe atopic dermatitis. VTAMA cream is currently indicated for plaque psoriasis in adults and atopic dermatitis in adults and pediatric patients aged 2 years and older.

Organon & Co. (OGN) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/OGN/
This page provides a comprehensive overview of Organon & Co. (OGN) stock, including real-time and overnight trading prices, historical data, and key financial metrics. It also offers various tools for market analysis such as charts, statistics, and links to research reports, catering to investors tracking the company's performance.

Q3 revenue fell to $1.57B at Organon (OGN), but profit moved the other way.

https://www.stocktitan.net/sec-filings/OGN/10-q-organon-co-quarterly-earnings-report-41ebdf003e87.html
Organon (OGN) reported a 2% decrease in third-quarter 2026 revenue to $1.574 billion, down from $1.602 billion a year earlier, but net income rose to $164 million from $160 million. For the first nine months of 2026, revenue was $4.592 billion (down 2%) and net income was $418 million (up from $392 million), with operating cash flow increasing to $702 million. The company's acquisition by Sun Pharmaceutical Industries Limited for $14.00 per share in cash is expected to close by early 2027, following stockholder approval in July 2026.

Press Release: Organon Announces Quarterly Dividend

https://www.moomoo.com/news/post/1003012909/press-release-organon-announces-quarterly-dividend
Organon (NYSE: OGN) has announced a quarterly dividend of $0.36 per share of common stock, payable on December 14, 2023, to shareholders of record as of November 20, 2023. This marks the tenth consecutive quarterly dividend declared by the company since its spin-off.
Advertisement

Form 8K Organon & Co For: 30 October By Investing.com

https://za.investing.com/news/stock-market-news/form-8k-organon--co-for-30-october-93CH-4539164
This article reports that Organon & Co. filed a Form 8K on October 30, 2026. The filing is a routine disclosure document for significant events that shareholders should know about. No specific details of the 8K filing are provided in this brief announcement.

Organon declares $0.02 quarterly dividend payable in December

https://www.investing.com/news/company-news/organon-declares-002-quarterly-dividend-payable-in-december-93CH-4987465
Organon & Co. (NYSE:OGN) announced a quarterly dividend of $0.02 per share of common stock. The dividend is scheduled for payment on December 10, 2026, to shareholders recorded as of November 9, 2026. Organon is a global healthcare company specializing in Women's Health and General Medicines, operating in over 140 markets.

Form 8K Organon & Co For: 30 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-organon--co-for-30-october-93CH-4917966
Organon & Co (OGN) filed a Form 8K for October 30, as reported by Investing.com. The filing indicates a significant event or announcement from the company on that date.

Organon & Co. (OGN) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/OGN/seasonality/
The Yahoo Finance page for Organon & Co. (OGN) displays its seasonal returns chart, showing the average monthly price return from 2021 to 2026. The stock's current price is 13.81 USD, with a slight increase in after-hours trading. The page provides various data points, including summary, news, research, and historical data, but the chart content is not fully rendered.

Organon stock reaches new 52-week high at USD 13.83

https://www.ad-hoc-news.de/boerse/news/nebenwerte/organon-stock-reaches-new-52-week-high-at-usd-13-83/70431301
Organon stock reached a new 52-week high of USD 13.83 during trading on October 29, 2026. The company is expected to file its third-quarter 2026 results soon, and its proposed acquisition by Sun Pharmaceutical Industries remains a key focus for investors. The article also provides details on Organon's market data and its Euro quote.
Advertisement

Organon & Co stock hits 52-week high at 13.83 USD

https://www.investing.com/news/company-news/organon--co-stock-hits-52week-high-at-1383-usd-93CH-4984951
Organon & Co (OGN) stock has reached a new 52-week high of 13.83 USD, reflecting a significant 1-year change of 110.05% and indicating substantial growth and investor confidence. InvestingPro Tips suggest the company has been profitable over the last twelve months and net income is expected to grow this year.

Weekly Recap: Sun Pharma deal for Organon & Co. and No Q3 '26 milestones

https://www.tradingview.com/news/tradingview:b49a44ff7285c:0-weekly-recap-sun-pharma-deal-for-organon-co-and-no-q3-26-milestones/
Sun Pharma is set to acquire Organon & Co. (NYSE:OGN) in an all-cash deal worth $11.75 billion, a move expected to significantly expand Sun Pharma's global presence and women's health portfolio. Meanwhile, Organon & Co. has reiterated that it anticipates no milestone-related expenses in Q3 2026. This recap highlights the key developments concerning both companies.

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

https://ca.finance.yahoo.com/news/organon-co-ogn-trending-stock-120002806.html
Organon & Co. (OGN) has been a trending stock on Zacks.com, prompting an analysis of its performance drivers. The pharmaceutical company has seen a modest +0.2% return in the past month, outperforming the S&P 500 but trailing its industry. Based on earnings estimate revisions, revenue forecasts, past results, and valuation, Organon currently holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market.

Zuellig Pharma and Organon Unveil New Marvelon Packaging

https://kiripost.com/stories/zuellig-pharma-and-organon-unveil-new-marvelon-packaging
Zuellig Pharma and Organon have announced the unveiling of new packaging for Marvelon. The article headline indicates a collaboration between the two companies on this product update. No further details about the packaging or product changes are provided in the snippet.

Organon & Co. Estimates – NYSE:OGN

https://www.tradingview.com/symbols/NYSE-OGN/financials-estimates/
This article provides a financial overview of Organon & Co. (NYSE: OGN) on TradingView, detailing access to reported financial data and analyst estimates. Users can explore income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends. The platform also offers tools for technical analysis and forecasting.
Advertisement

Sun Pharma Raises Rs 10,000 Cr In Debt To Fund Organon Acquisition

https://www.tradingview.com/news/moodys:5c0e30ac738d1:0-sun-pharma-raises-rs-10-000-cr-in-debt-to-fund-organon-acquisition/
Sun Pharmaceutical Industries is raising Rs 10,000 crore through rupee-denominated bonds to partly refinance bridge loans for its USD 11.75 billion acquisition of US healthcare company Organon. The bond issue, consisting of two tranches with maturities in 2031, will help finance the remaining amount needed after Sun Pharma uses USD 2 billion-2.5 billion from its cash surplus. Institutional investors, including insurance companies and pension funds, are expected to participate, with Crisil Ratings assigning an AAA/Stable rating to the NCDs.

Sun Pharma to raise Rs 10,000 crore to part-finance Organon deal

https://m.economictimes.com/markets/stocks/news/sun-pharma-to-raise-rs-10k-crore-to-part-finance-organon-deal/articleshow/135079260.cms
Sun Pharmaceutical Industries plans to raise ₹10,000 crore through two tranches of rupee-denominated bonds to help refinance bridge loans taken for its $11.75 billion acquisition of US healthcare company Organon. The bonds will have maturities in 2031, with one ₹7,000 crore tranche carrying an 8.20% coupon and a ₹3,000 crore tranche with an 8.05% coupon, including a put option in 2028. Institutional investors like SBI Pension Fund and ICICI Prudential Mutual Fund are expected to participate in the issue.

Organon plans third-quarter filing on October 19 for Organon stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/organon-plans-third-quarter-filing-on-october-19-for-organon-stock/70376556
Organon announced its plan to file its third-quarter 2026 Form 10-Q on October 19, 2026, and has suspended its quarterly earnings calls due to a pending acquisition. The company reported a 2.30 percent year-over-year revenue decline to USD 1.56 billion in Q2 2026, with Organon stock trading at EUR 12.26 after hours on October 20, 2026. This filing will provide key financial updates, especially regarding revenue, earnings, and the impact of milestone costs.

Organon Q3FY26 Results: Filing via 10-Q amid Sun Pharma deal

https://scanx.trade/stock-market-news/companies/organon-q3fy26-results-filing-via-10-q-sun-pharma-deal/53956092
Organon (NYSE: OGN) will release its Q3 2026 financial results through a Form 10-Q filing with the SEC, suspending quarterly earnings calls due to its pending acquisition by Sun Pharmaceutical Industries Limited. The company does not anticipate recording any milestone expenses for the quarter and will also file a Form 8-K for non-GAAP financial measure reconciliation.

Organon & Co Says It Does Not Expect To Record Milestone Expense In Q3 2026

https://www.tradingview.com/news/reuters.com,2026:newsml_FWN463087:0-organon-co-says-it-does-not-expect-to-record-milestone-expense-in-q3-2026/
Organon & Co announced that it does not anticipate recording a milestone expense in the third quarter of 2026. This information was reported by Reuters and published on TradingView. The full article is available with unlimited access for TradingView users.
Advertisement

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

https://finance.yahoo.com/healthcare/articles/organon-report-third-quarter-2026-113000757.html
Organon (NYSE: OGN) announced it will release its third-quarter 2026 financial results via its Form 10-Q filing with the SEC, along with a Form 8-K for non-GAAP financial measures. Due to the pending acquisition by Sun Pharmaceutical Industries Limited, Organon has suspended its quarterly earnings calls. The company does not anticipate recording any milestone expense in Q3 2026.

Organon stock sits 17.15 percent above USD 11.40 consensus target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/organon-stock-sits-17-15-percent-above-usd-11-40-consensus-target/70350552
Organon stock is currently trading 17.15% above the consensus target of $11.40, according to seven brokerages that issued a "Reduce" rating. The company's third-quarter results are estimated for November 9, 2026, with revenue projected at $1.58 billion. The discrepancy between the current stock price and the target adds significance to the upcoming earnings report.

ORGANON & CO - NO NEW SAFETY SIGNALS IDENTIFIED DURING THREE YEARS OF EXTENDED MIUDELLA USE

https://www.moomoo.com/news/flash/1001439873/organon-co-no-new-safety-signals-identified-during-three-years
Organon & Co announced that a three-year follow-up study on the extended use of its contraceptive device, MIUDELLA, found no new safety signals. The study, conducted post-market approval, reinforces the established safety profile of MIUDELLA for long-term contraception. This finding is significant for healthcare providers and individuals seeking reliable birth control options.

Organon & Co - FDA Accepts Snda for Miudella

https://www.moomoo.com/news/flash/1001439995/organon-co-fda-accepts-snda-for-miudella-for-extended-use
Organon & Co. announced that the FDA has accepted its Supplemental New Drug Application (sNDA) for Miudella. This acceptance marks a significant step forward for the pharmaceutical company regarding its new drug.

Organon reports six‑year MIUDELLA data as FDA reviews longer use

https://mugglehead.com/organon-miudella-six-year-phase-3-fda-review/
Organon (NYSE: OGN) has reported interim Phase 3 data for its hormone-free IUD, MIUDELLA, supporting a bid to extend its approved duration from three to six years. The FDA is currently reviewing a supplemental New Drug Application, with a decision expected in Q2 2027. The six-year results from a single-arm study showed a cumulative Pearl Index of 0.93 and a Kaplan-Meier pregnancy rate of 3.9%, with no new safety signals reported, though some participants discontinued due to heavy menstrual bleeding and painful periods.
Advertisement

Organon stock sits 0.51 percent below its 52-week high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/organon-stock-sits-0-51-percent-below-its-52-week-high/70333632
Organon stock is currently trading 0.51% below its 52-week high, with a P/E ratio of 17.87 and a market capitalization of $3.6 billion as of October 15, 2026. The company, which focuses on prescription medicines, women's health, biosimilars, and established brands, reported Q2 2026 revenue of $1.56 billion and net income of $108 million. The stock's current NYSE quote is $13.76, near the upper end of its $5.69 to $13.83 annual range.

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

https://sg.finance.yahoo.com/news/investors-heavily-search-organon-co-120003655.html
Organon (OGN) stock has recently seen significant investor interest. Despite a modest 0.8% return over the past month, the company's valuation metrics and earnings estimate revisions are key factors for its future performance. Organon currently holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market in the near term.

Organon & Co stock hits 52-week high at 13.79 USD

https://www.investing.com/news/company-news/organon--co-stock-hits-52week-high-at-1379-usd-93CH-4937393
Organon & Co (OGN) stock has reached a new 52-week high of $13.79, reflecting a 34.47% increase over the past year. InvestingPro analysis suggests the stock is undervalued with a strong free cash flow yield. The company also announced upcoming presentations of Phase 3 data for VTAMA cream at the Society for Pediatric Dermatology Annual Meeting, highlighting ongoing dermatological research.

Organon stock presents new VTAMA analysis ahead of November results

https://www.ad-hoc-news.de/boerse/news/corporate-news/organon-stock-presents-new-vtama-analysis-ahead-of-november-results/70227530
Organon stock (OGN) is gaining investor attention with new real-world analysis of its VTAMA cream for atopic dermatitis, presented ahead of its November earnings report. Despite a 2.3% revenue decline in Q2 2026, the company's stock is trading near its 52-week high, valued at $13.72 as of October 2, 2026. This positive product development and a recent regulatory milestone for its MIUDELLA intrauterine device are central to the company's current narrative, focusing on women's health and specialty medicines, despite analyst targets remaining below the current stock price.

XS233225070 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/TRADEGATE-XS233225070/profile/
This article provides a detailed profile of the Organon & Co. 2.875% bond (XS233225070) maturing on April 30, 2028. It outlines key facts about the bond and its issuer, Organon & Co., including issue date, maturity, and face value. The profile also details interest payment information, such as the fixed semi-annual coupon rate, upcoming payout schedules, and bond redemption specifics.
Advertisement

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

https://www.biospace.com/press-releases/organon-to-present-new-real-world-analysis-of-vtama-tapinarof-cream-1-at-the-2026-fall-clinical-dermatology-conference
Organon announced that new real-world analysis of VTAMA (tapinarof) cream, 1%, for atopic dermatitis (AD) will be presented at the 2026 Fall Clinical Dermatology Conference. This analysis will evaluate the cream's effectiveness in real-world settings, including improvements in physician-reported outcomes and patient-reported itch scores. VTAMA cream is indicated for topical treatment of plaque psoriasis and atopic dermatitis in adults and pediatric patients aged 2 years and older.

Organon presents VTAMA analysis: Organon stock gains 1.16 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/organon-presents-vtama-analysis-organon-stock-gains-1-16-percent/70213208
Organon stock saw a 1.16 percent gain after the company announced it would present new real-world data for its VTAMA cream at the 2026 Fall Clinical Dermatology Conference. The analysis focuses on VTAMA's effectiveness in patients with atopic dermatitis, evaluating physician-reported outcomes and patient itch scores, complementing existing clinical trial data. Despite the stock gain, analyst consensus remains cautious with a "Reduce" rating and an average price target below the current market quote.

One of the first large-scale real-world analyses of an eczema cream will be shown

https://www.stocktitan.net/news/OGN/organon-to-present-new-real-world-analysis-of-vtama-tapinarof-cream-o4l2d6fb34kn.html
Organon (NYSE: OGN) announced it will present new real-world analysis of its VTAMA (tapinarof) cream, 1% for atopic dermatitis at the 2026 Fall Clinical Dermatology Conference. This analysis will be one of the first large-scale real-world effectiveness studies of VTAMA cream in patients with atopic dermatitis, evaluating improvements in physician-reported and patient-reported outcomes. VTAMA cream is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of plaque psoriasis and atopic dermatitis in adults and pediatric patients aged 2 years and older.

Revenue per share of Organon & Co. – HAN:7XP

https://www.tradingview.com/symbols/HAN-7XP/financials-statistics-and-ratios/revenue-per-share/
The article focuses on the revenue per share for Organon & Co. (HAN:7XP) listed on the Hannover Stock Exchange. It provides financial data and indicates that the market is currently closed with no trades. The content primarily features navigation and footer information related to the TradingView platform.

Tangible book value per share of Organon & Co. – HAN:7XP

https://www.tradingview.com/symbols/HAN-7XP/financials-statistics-and-ratios/book-tangible-per-share/
This article provides the tangible book value per share for Organon & Co. (HAN:7XP) on the Hannover Stock Exchange. The current market status is closed with no trades recorded. The data is presented within the context of financial overview for the company.
Advertisement

Organon & Co. Revenue Breakdown – HAN:7XP

https://www.tradingview.com/symbols/HAN-7XP/financials-segments/
Organon & Co. generated 5.29 billion EUR in revenue last year. The "Established Brands" segment was the top-performing, contributing 3.14 billion EUR. Geographically, Europe and Canada were the largest contributors, accounting for 1.38 billion EUR.

Sun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: Report

https://www.ndtvprofit.com/business/sun-pharma-plans-rs-10-000-crore-rupee-debt-sale-to-refinance-organon-deal-report-12114633
Sun Pharmaceutical Industries is reportedly planning to raise around Rs 10,000 crore through a rupee-denominated debt sale. This move is intended to partly refinance a bridge loan taken for its acquisition of US healthcare company Organon & Co. The fundraising involves bonds with maturities of two, three, and four years, as Indian companies increasingly look to the domestic debt market due to higher global borrowing costs.

ORGANON & CO. - MIUDELLA ANTICIPATED TO BE COMMERCIALLY AVAILABLE IN LATE 2026

https://www.moomoo.com/news/flash/23174731/organon-co-miudella-anticipated-to-be-commercially-available-in-late
Organon & Co. announced that its new product, Miudella, is expected to become commercially available in late 2026. This announcement indicates the company's progress in its product pipeline and provides a timeline for market entry.

Organon Backs Women’s Health Efforts Across India

https://www.pharmacy.biz/organon-womens-health-support-india/
Organon announced two grants in India to support women's health, focusing on adolescent health in Bihar and expanding contraceptive access in Uttar Pradesh. These initiatives, in partnership with Population Services International India and Ipas Development Foundation, address different stages of a woman's life, from education to reproductive choices. The effort follows Sun Pharmaceutical Industries' acquisition of Organon, highlighting a significant investment in women's health in India.

how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com

https://www.investing.com/news/investment-ideas/how-investingpro-spotted-organons-65-gain-in-healthcare-sector-93CH-4905325
InvestingPro accurately predicted Organon & Co.'s significant stock surge, identifying it as an undervalued pharmaceutical company in early 2026. Despite an initial downturn, InvestingPro's Fair Value analysis highlighted strong fundamentals and an intrinsic value well above its trading price. This insight led to a 64.63% return for the stock, validated by catalysts like acquisition bids and pipeline advancements.
Advertisement

Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid

https://manufacturing.economictimes.indiatimes.com/news/life-sciences/sun-pharma-gets-ratings-boost-from-moodys-sp-over-11-75-bn-organon-co-acquisition-bid/133921365
Rating agencies Moody's and S&P have assigned investment-grade ratings to Sun Pharmaceutical Industries following its proposed $11.75 billion acquisition of US-based Organon & Co. This acquisition is expected to significantly strengthen Sun Pharma's business position, almost doubling its revenue and expanding its geographic reach, particularly in women's health and biosimilars. The transaction, backed by a $12 billion bridge loan and substantial cash reserves, is anticipated to close by March 2027.

Organon & Co stock hits 52-week high at $13.78

https://www.investing.com/news/company-news/organon--co-stock-hits-52week-high-at-1378-93CH-4884181
Organon & Co's stock has reached a new 52-week high of $13.78, marking a 46.07% increase over the past year, driven by significant developments. These include a global licensing agreement for the hormone-free IUD Miudella, exclusive commercialization rights for biosimilar PYZCHIVA in Canada, and expanded FDA indications for biosimilar TOFIDENCE. The company is also presenting new Phase 3 data for VTAMA cream, showcasing ongoing efforts to expand its product offerings and market presence.

Organon & Co stock hits 52-week high at $13.78 By Investing.com

https://za.investing.com/news/stock-market-news/organon--co-stock-hits-52week-high-at-1378-93CH-4450144
Organon & Co's stock reached a 52-week high of $13.78, marking a 46.07% increase over the past year due to positive market momentum and investor confidence. This surge follows recent company developments, including a licensing agreement for Miudella, commercialization rights for PYZCHIVA, and expanded FDA indications for TOFIDENCE.

Organon & Co stock hits 52-week high at $13.78 By Investing.com

https://ng.investing.com/news/stock-market-news/organon--co-stock-hits-52week-high-at-1378-93CH-2681351
Organon & Co's stock has reached a new 52-week high of $13.78, marking a 46.07% increase over the past year, driven by investor confidence and recent company developments. These developments include a global licensing agreement for the hormone-free copper IUD Miudella, exclusive commercialization rights for the biosimilar PYZCHIVA in Canada, and expanded FDA approvals for its biosimilar TOFIDENCE. The company is also preparing to present new Phase 3 data for VTAMA cream in atopic dermatitis.

Organon & Co. (OGN) Short Interest & Short Float | Updated Aug 2026 $OGN

https://www.marketbeat.com/stocks/NYSE/OGN/short-interest/
As of August 14, 2026, Organon & Co. (OGN) had a short interest of 15.14 million shares, a 9.92% decrease from the prior report, representing 5.86% of its public float. The short interest ratio is 6.1 days to cover. This report details the historical short interest data for OGN, along with comparisons to peers and explanations of key short interest metrics.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement